Zoetis to acquire Nexvet Veterinary Biologic Therapeutics Co.April 13, 2017Zoetis Inc. announced it will purchase Nexvet Biopharma veterinary biologic therapeutics company for US $6.72 per share, or a valuation of approximately US $85 million. Pending approval, the purchase is expected to be completed during the second half of 2017.
SPONSORED CONTENTThe Case for Year-Round Heartworm Prevention and Affordable OptionsVeterinarians are often more than just clinicians - they’re advisors, educators, and, increasingly, financial counselors. In today’s economy, pet owners may hesitate to invest in year-round prevention due to budget constraints; but, skipping even a few months of heartworm protection can have serious consequences. + Learn More
